Liz Parrish, founder of BioViva Sciences discusses the objective improvements in her biomarkers after taking gene therapy for telomerase and follastatin.
Gene Therapy CEO and “patient zero” says her telomere length went from 6,710 DNA base pairs to 7,330 base pair in just six months.
We chat with BioViva CEO Liz Parrish, who has heroically injected herself with a live virus meant to transfect her with two genes- telomerase and follistatin.
Meet Liz Parris, CEO of BioViva, who last week divulged that that she herself was actually “Patient zero” or first patient was transfected. We are left to hope for the best, say thanks to Liz Parrish for taking a bold step towards her own personal immortality, and will watch and wait.
DISCLAIMER: This website is for educational purposes only and is not for advertising. Telomerase activators and nanovesicles are not FDA-approved to prevent or treat any disease and anecdotes are not scientific proof of efficacy. All patients were treated in the context of a fully informed and legally-protected patient physician relationship.
Required fields
© 2020 Recharge Biomedical
Exosomes and TA-65 are not FDA-approved to prevent or treat any illness
